Jiangxi Fushine Pharmaceutical Co., Ltd. (SHE:300497)
China · Delayed Price · Currency is CNY 15.39
+0.09 (0.59%)
Jun 1, 2026, 3:04 PM CST
SHE:300497 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 1,306 | 1,182 | 1,173 | 1,597 | 1,633 | 1,388 |
Other Revenue | 3.4 | 3.4 | 4.88 | 12.39 | 14.28 | 41.15 |
| 1,309 | 1,185 | 1,178 | 1,610 | 1,647 | 1,430 | |
Revenue Growth (YoY) | 22.21% | 0.61% | -26.83% | -2.28% | 15.23% | -4.25% |
Cost of Revenue | 1,018 | 995.17 | 1,124 | 1,471 | 1,433 | 996.18 |
Gross Profit | 291.53 | 189.82 | 53.88 | 138.32 | 214.38 | 433.36 |
Selling, General & Admin | 160.18 | 151.94 | 152.9 | 193.55 | 179.91 | 163.47 |
Research & Development | 58.42 | 59.5 | 74.66 | 97.45 | 77.45 | 78.51 |
Other Operating Expenses | 42.2 | 13.05 | 9.67 | 16.53 | 15.23 | 14.58 |
Operating Expenses | 277.32 | 230.92 | 236.36 | 308.44 | 273.38 | 260.29 |
Operating Income | 14.21 | -41.1 | -182.48 | -170.12 | -59 | 173.07 |
Interest Expense | -48.04 | -46.24 | -40.58 | -42.03 | -41.1 | -24.92 |
Interest & Investment Income | 4.81 | 5.51 | 6.68 | 9.29 | 23.29 | 16.4 |
Currency Exchange Gain (Loss) | -3.31 | -3.31 | 8.29 | 7.9 | 18.81 | -3.81 |
Other Non Operating Income (Expenses) | -2.3 | 3.83 | -2.48 | -4.54 | -3.51 | -0.21 |
EBT Excluding Unusual Items | -34.63 | -81.32 | -210.57 | -199.5 | -61.5 | 160.53 |
Impairment of Goodwill | - | - | - | -1.15 | -1.07 | - |
Gain (Loss) on Sale of Investments | -14.23 | -13.82 | -13.99 | -15.5 | -82.93 | -131.99 |
Gain (Loss) on Sale of Assets | -1.33 | -0.38 | -0.1 | 0.08 | 0.41 | -0.06 |
Asset Writedown | -2.86 | -6.58 | -101.63 | -23.74 | -12.82 | -2.01 |
Other Unusual Items | 39.33 | 36.89 | 37.73 | 6.64 | 15.21 | 28.61 |
Pretax Income | -13.73 | -65.21 | -288.56 | -233.17 | -142.71 | 55.07 |
Income Tax Expense | -9.6 | -2.24 | -8.11 | -9.91 | 21.47 | 15.53 |
Earnings From Continuing Operations | -4.12 | -62.97 | -280.45 | -223.26 | -164.17 | 39.54 |
Minority Interest in Earnings | 8.05 | 7.94 | 8.35 | 22.46 | 22.7 | 9.29 |
Net Income | 3.93 | -55.03 | -272.1 | -200.8 | -141.47 | 48.83 |
Net Income to Common | 3.93 | -55.03 | -272.1 | -200.8 | -141.47 | 48.83 |
Net Income Growth | - | - | - | - | - | -84.71% |
Shares Outstanding (Basic) | 545 | 550 | 534 | 543 | 544 | 543 |
Shares Outstanding (Diluted) | 545 | 550 | 534 | 543 | 544 | 543 |
Shares Change (YoY) | -1.19% | 3.14% | -1.69% | -0.26% | 0.29% | 17.25% |
EPS (Basic) | 0.01 | -0.10 | -0.51 | -0.37 | -0.26 | 0.09 |
EPS (Diluted) | 0.01 | -0.10 | -0.51 | -0.37 | -0.26 | 0.09 |
EPS Growth | - | - | - | - | - | -86.96% |
Free Cash Flow | -106.67 | -162.21 | 45.89 | -306.99 | -580.26 | -607.28 |
Free Cash Flow Per Share | -0.20 | -0.29 | 0.09 | -0.57 | -1.07 | -1.12 |
Gross Margin | 22.27% | 16.02% | 4.57% | 8.59% | 13.01% | 30.31% |
Operating Margin | 1.09% | -3.47% | -15.49% | -10.57% | -3.58% | 12.11% |
Profit Margin | 0.30% | -4.64% | -23.10% | -12.47% | -8.59% | 3.42% |
Free Cash Flow Margin | -8.15% | -13.69% | 3.90% | -19.07% | -35.23% | -42.48% |
EBITDA | 205.41 | 146.08 | -11.39 | -10.66 | 64.84 | 271.64 |
EBITDA Margin | 15.69% | 12.33% | -0.97% | -0.66% | 3.94% | 19.00% |
D&A For EBITDA | 191.2 | 187.18 | 171.09 | 159.46 | 123.84 | 98.57 |
EBIT | 14.21 | -41.1 | -182.48 | -170.12 | -59 | 173.07 |
EBIT Margin | 1.09% | -3.47% | -15.49% | -10.57% | -3.58% | 12.11% |
Effective Tax Rate | - | - | - | - | - | 28.20% |
Revenue as Reported | 1,309 | 1,185 | 1,178 | 1,610 | 1,647 | 1,430 |
Advertising Expenses | - | 4.24 | 4.05 | 6.19 | - | 4.19 |